Main Menu

ICR strategic commercial partner raises $226.5m in financing

A composite image of the ICR and Apollo Therapeutics logos

Apollo Therapeutics, a strategic partner of The Institute of Cancer Research, has raised more than $226m from investors to fund its ongoing collaboration with the ICR and other academic partners.

The funding has been provided by a consortium of investors led by healthcare investment firm Patient Square Capital – and will be used by Apollo to advance its existing programmes through clinical development and to acquire new, clinical stage programmes.

The ICR announced a new strategic collaboration with Apollo last year. The company was founded by and collaborates with Imperial College London, the University of Cambridge and UCL and also has a strategic agreement with Kings College London, as well as the ICR.

Successful Apollo programmes include the development of a new treatment for acute myeloid leukaemia, which it is developing in collaboration with Professor Holger Auner and Professor Matthew Fuchter from Imperial.

Apollo Therapeutics is advancing a pipeline of therapeutic programmes based on breakthrough discoveries. The company identifies and develops pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options.

Dr Jon Wilkinson, Director of Business and Innovation at the ICR, said:
“We’re very pleased to be working with Apollo as a strategic partner. Our relationship with them is a great example of how we are working in innovative new ways to try to commercialise our discoveries and, ultimately, deliver new treatments to patients.”


industry partnerships jon wilkinson apollo therapeutics apollo
comments powered by Disqus